Article

ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell Lines

2022-06-21

Abstract excerpt

Metastatic skin cutaneous melanomas remain a significant clinical problem. In particular, those melanomas that do not contain a gain-of-function BRAF allele remain challenging to treat because of the paucity of targets for effective therapeutic intervention. Thus, here we investigate the role of the ERBB4 receptor tyrosine kinase in skin cutaneous melanomas that contain wild-type BRAF alleles (“ BRAF WT melanom...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 12176346-d2b1-57a4-a53b-cac0a7c2a269
DOI: 10.1101/2022.06.20.22276663

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell LinesDOI 10.1101/2022.06.20.22276663Read

<i>ERBB4</i>Mutant Alleles Found in<i>BRAF</i>WT Melanomas That Drive the Proliferation of a<i>BRAF</i>WT Melanoma Cell LineSemantic proximity Read

Human melanoma cell lines that possess wild-type <i>BRAF</i> alleles but are dependent on <i>ERBB4</i> and <i>ERBB2</i>Semantic proximity Read

A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.Semantic proximity Read

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read

KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growthSemantic proximity Read

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read

Melanoma Mutagenesis and Aberrant Cell SignalingSemantic proximity Read

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.Semantic proximity Read

Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.Semantic proximity Read

A growing family: adding mutated Erbb4 as a novel cancer target.Semantic proximity Read

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.Semantic proximity Read